Literature DB >> 34740950

Imaging PD-L1 Expression in Melanoma Brain Metastases.

Sridhar Nimmagadda1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34740950      PMCID: PMC9157733          DOI: 10.2967/jnumed.121.263209

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   11.082


× No keyword cloud information.
  12 in total

1.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

Authors:  Dirk Schadendorf; F Stephen Hodi; Caroline Robert; Jeffrey S Weber; Kim Margolin; Omid Hamid; Debra Patt; Tai-Tsang Chen; David M Berman; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

Review 2.  Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.

Authors:  Anna S Berghoff; Vyshak A Venur; Matthias Preusser; Manmeet S Ahluwalia
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

3.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier F Ferrucci; Michael Smylie; David Hogg; Andrew Hill; Ivan Márquez-Rodas; John Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Lars Bastholt; Jasmine I Rizzo; Agnes Balogh; Andriy Moshyk; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

Review 4.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

5.  A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.

Authors:  Richard S P Huang; James Haberberger; Eric Severson; Daniel L Duncan; Amanda Hemmerich; Claire Edgerly; Naomi Lynn Ferguson; Erik Williams; Julia Elvin; Jo-Anne Vergilio; Jonathan Keith Killian; Douglas I Lin; Julie Tse; Matthew Hiemenz; Clarence Owens; Natalie Danziger; Priti S Hegde; Jeffrey Venstrom; Brian Alexander; Jeffrey S Ross; Shakti H Ramkissoon
Journal:  Mod Pathol       Date:  2020-09-03       Impact factor: 7.842

6.  Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.

Authors:  Grant M Fischer; Ali Jalali; David A Kircher; Won-Chul Lee; Jennifer L McQuade; Lauren E Haydu; Aron Y Joon; Alexandre Reuben; Mariana P de Macedo; Fernando C L Carapeto; Chendong Yang; Anuj Srivastava; Chandrashekar R Ambati; Arun Sreekumar; Courtney W Hudgens; Barbara Knighton; Wanleng Deng; Sherise D Ferguson; Hussein A Tawbi; Isabella C Glitza; Jeffrey E Gershenwald; Y N Vashisht Gopal; Patrick Hwu; Jason T Huse; Jennifer A Wargo; P Andrew Futreal; Nagireddy Putluri; Alexander J Lazar; Ralph J DeBerardinis; Joseph R Marszalek; Jianjun Zhang; Sheri L Holmen; Michael T Tetzlaff; Michael A Davies
Journal:  Cancer Discov       Date:  2019-02-20       Impact factor: 39.397

7.  18F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study.

Authors:  Pieter H Nienhuis; Inês F Antunes; Andor W J M Glaudemans; Mathilde Jalving; David Leung; Walter Noordzij; Riemer H J A Slart; Erik F J de Vries; Geke A P Hospers
Journal:  J Nucl Med       Date:  2021-09-09       Impact factor: 11.082

Review 8.  Antagonists of PD-1 and PD-L1 in Cancer Treatment.

Authors:  Evan J Lipson; Patrick M Forde; Hans-Joerg Hammers; Leisha A Emens; Janis M Taube; Suzanne L Topalian
Journal:  Semin Oncol       Date:  2015-06-10       Impact factor: 4.929

9.  Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression.

Authors:  David J Donnelly; R Adam Smith; Paul Morin; Daša Lipovšek; Jochem Gokemeijer; Daniel Cohen; Virginie Lafont; Tritin Tran; Erin L Cole; Martin Wright; Joonyoung Kim; Adrienne Pena; Daniel Kukral; Douglas D Dischino; Patrick Chow; Jinping Gan; Olufemi Adelakun; Xi-Tao Wang; Kai Cao; David Leung; Samuel J Bonacorsi; Wendy Hayes
Journal:  J Nucl Med       Date:  2017-10-12       Impact factor: 10.057

Review 10.  Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges.

Authors:  Sridhar Nimmagadda
Journal:  Cancers (Basel)       Date:  2020-10-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.